Molecular and Structural Imaging for Alzheimer's Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you may be excluded if you are on medications that affect brain structure or metabolism, like chemotherapy.
What data supports the effectiveness of the drug C-11 PiB, Pittsburgh Compound B, [11C]6-OH-BTA-1, (N-Methyl-[11C])2-(4'-methylamino-phenyl)-6-hydroxy-benzo-thiazole, [11C]PiB, F-18 AV 1451, Tauvid, Flortaucipir F-18, 18F-AV-1451, 18F-T807, LY-3191748, T-807 F-18 for Alzheimer's disease?
Research shows that Flortaucipir F-18, a component of the drug, is effective in imaging tau protein tangles, which are a key feature of Alzheimer's disease. This helps in diagnosing and understanding the progression of the disease by showing the distribution and density of these tangles in the brain.12345
Is the imaging treatment for Alzheimer's disease safe for humans?
How does the treatment in the Alzheimer's imaging trial differ from other treatments?
This treatment uses advanced imaging techniques like PET scans with specific tracers to visualize and measure amyloid and tau proteins in the brain, which are associated with Alzheimer's disease. Unlike traditional treatments that focus on symptom management, this approach aims to provide a detailed understanding of the disease's progression and response to potential therapies.18101112
What is the purpose of this trial?
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
Research Team
Jennifer Whitwell, Ph.D.
Principal Investigator
Mayo Clinic
Eligibility Criteria
This study is for adults over 21 with Atypical Alzheimer's Disease, specifically those diagnosed with Logopenic Aphasia or Posterior Cortical Atrophy. Participants must have a person to report on their functioning and speak English as their primary language. They can't join if they've had strokes, tumors, severe memory issues early on, other neurodegenerative diseases, very poor vision, are pregnant/breastfeeding, or have MRI contraindications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo two Tau PET scans and two PiB PET scans to assess amyloid and tau burden
Follow-up
Participants are monitored for changes in amyloid and tau burden over a one year period
Treatment Details
Interventions
- C-11 PiB
- F-18 AV 1451
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Institute on Aging (NIA)
Collaborator